mCBM40
Biologicalexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 13, 2021 (NCT05093530)
Timeline
Indications
Mechanism of action
- SARS-CoV-2INHIBITOR
SARS-CoV-2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05507567 | Phase 2 | Aug 12, 2022 | Pneumagen Ltd. |
| NCT05093530 | Phase 1 | Oct 13, 2021 | Pneumagen Ltd., ProPharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pneumagen Ltd. | For profit | 2 | 2 | 2 | 2021 |
| ProPharma | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1